Table 1 Clinical and baseline characteristics of subjects.
Clinical characteristics | Survivor (51) | Non-survivor (92) | |
|---|---|---|---|
Outcome study patients for serum endotype in ARDS (n = 143) | |||
Age | 43.11 ± 1.76 | 46.9 ± 1.68 | |
Sex (M/F) | 31/20 | 59/33 | |
Primary diagnosis, (n) | Neurological (10) | Neurological (9) | |
Respiratory (16) | Respiratory (34) | ||
Cardiac (5) | Cardiac (5) | ||
Gastrointestinal (15) | Gastrointestinal (30) | ||
Tropical infections (4) | Tropical infections (10) | ||
Others (1) | Others (4) | ||
Comorbidities, (n) | Diabetes mellitus (12) | Diabetes mellitus (18) | |
Hypertension (9) | Hypertension (12) | ||
Diabetes + hypertension (14) | Diabetes + hypertension (28) | ||
Hypothyroidism (4) | Hypothyroidism (9) | ||
Chronic kidney disease (3) | Chronic kidneydisease (5) | ||
Chronic artery disease (2) | Chronic artery disease (3) | ||
Nil (7) | Nil (17) | ||
APACHE-II* | 13.56 ± 0.28 | 17.64 ± 0.29 | |
SOFA* | 7.78 ± 0.22 | 10.25 ± 0.20 | |
TLC* | 11.70 ± 0.73 | 19.94 ± 1.23 | |
PCT* | 1.87 ± 0.28 | 3.70 ± 0.65 | |
Serum creatinine* | 2.04 ± 0.23 | 2.80 ± 0.14 | |
Bilirubin | 1.40 ± 0.13 | 1.62 ± 0.09 | |
Length of hospital (days) stay | 21.94 ± 1.04 | 23.53 ± 1.11 | |
Days of mechanical ventilation | 15 ± 1.12 | 18.14 ± 1.01 | |
Length of ICU stay (days) | 17.92 ± 1.09 | 19.10 ± 1.04 | |
Total study patients for serum analysis (n = 265) | |||
Control subjects (n = 68) | ARDS patients (n = 197) | ||
Age | 48.33 ± 1.91 | 48.87 ± 1.14 | |
Sex | 42/26 | 111/86 | |
ARDS Subphenotype for serum samples | |||
Subphenotype 1 (n = 176) | Mild (62) | Moderate (72) | Severe (42) |
P/F ratio* | 248.29 ± 4.1 | 165.22 ± 3.2 | 84.14 ± 2.2 |
Age | 44.61 ± 2.1 | 47.125 ± 1.9 | 49.30 ± 2.2 |
Sex (M/F) | 37/25 | 44/28 | 27/15 |
Subphenotype 2 (n = 147) | Pulmonary etiologies (67) | Extra-pulmonary etiologies (80) | |
Age | 46.89 ± 1.91 | 42.63 ± 1.80 | |
Sex (M/F) | 43/24 | 48/32 | |
Outcome study patients for mBALF endotype in ARDS (n = 124) | |||
Clinical characteristics | Survivor (51) | Non-survivor (73) | |
Age | 43.09 ± 1.81 | 47.78 ± 2.01 | |
Sex (M/F) | 36/15 | 42/31 | |
Primary diagnosis, (n) | Neurological (8) | Neurological (6) | |
Respiratory (20) | Respiratory (30) | ||
Cardiac (3) | Cardiac (1) | ||
Gastrointestinal (13) | Gastrointestinal (24) | ||
Tropical infections (5) | Tropical infections (9) | ||
Others (2) | Others (3) | ||
Comorbidities, (n) | Diabetes mellitus (10) | Diabetes mellitus (16) | |
Hypertension (6) | Hypertension (10) | ||
Diabetes + hypertension (14) | Diabetes + hypertension (21) | ||
Hypothyroidism (5) | Hypothyroidism (7) | ||
Chronic kidneydisease (3) | Chronic kidneydisease (4) | ||
Chronic artery disease (3) | Chronic artery disease (1) | ||
Nil (10) | Nil (14) | ||
APACHE* | 13.96 ± 0.28 | 17.50 ± 0.32 | |
SOFA* | 7.09 ± 0.22 | 10.08 ± 0.23 | |
TLC* | 12.18 ± 0.83 | 20.86 ± 1.45 | |
PCT* | 1.59 ± 0.21 | 3.97 ± 0.82 | |
Serum creatinine* | 2.03 ± 0.23 | 2.83 ± 0.18 | |
Bilirubin | 1.37 ± 0.11 | 1.64 ± 0.10 | |
Length of hospital (days) stay | 24.8 ± 1.20 | 25.24 ± 1.13 | |
Days of mechanical ventilation | 16.92 ± 1.08 | 18.52 ± 1.09 | |
Length of ICU stay (days) | 20.27 ± 1.23 | 19.09 ± 1.10 | |
Total study patients for mBALF analysis (n = 199) | |||
Study patients | Control (n = 40) | ARDS (n = 159) | |
Age | 47.8 ± 2.27 | 46.03 ± 1.24 | |
Sex | 25/15 | 89/70 | |
ARDS Subphenotype for mBALF samples | |||
Subphenotype 1 (n = 146) | Mlild (36) | Moderate (66) | Severe (44) |
P/F ratio* | 247.91 ± 5.6 | 159.18 ± 3.7 | 80.31 ± 2.9 |
Age | 46.22 ± 2.8 | 44.9 ± 2.0 | 49.15 ± 2.1 |
Sex (M/F) | 22/14 | 41/25 | 25/19 |
Subphenotype 2 (n = 128) | Pulmonary etiologies (60) | Extra-pulmonary etiologies (68) | |
Age | 43.28 ± 2.0 | 47.55 ± 1.90 | |
Sex (M/F) | 38/22 | 45/23 | |
